NCT03263260Completed
Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent
Prospective, Multicentric, Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent for Treatment of Patients With Native Coronary Artery Lesions (Inspiron Real Life II)
Source: ClinicalTrials.gov · Last updated 4 Sept 2024
Brief summary (registry, in English)
Post-marketing, prospective, multicentric, non-randomized registry to evaluate the safety and efficacy of Inspiron Sirolimus Eluting Coronary Stent at the treatment of "real-world" patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2504 (actual)
- First submitted
- 24 Aug 2017
- Start date
- 2 Jun 2017
- Primary completion date
- 15 Dec 2022
- Lead sponsor
- Scitech Produtos Medicos SA
- Diseases
- Coronary artery disease
- NCT number
- NCT03263260
What you commit to
- Study type: Observational
- Participants enrolled: 2504
- From 2 Jun 2017 to the primary completion date, 15 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Safein Vein or Left Internal Mammary artery Grafts
Who the study is looking for
- alll patients that have been treated with the Inspiron Sirolimus Eluting Stent older and 18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| União Brasileira de Educação e Assistência - Hospital São Lucas da PUC - RS Coordinator of this site? Confirm its status | Porto Alegre | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.